These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 25564105)

  • 1. Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.
    Metzger DS; Donnell D; Celentano DD; Jackson JB; Shao Y; Aramrattana A; Wei L; Fu L; Ma J; Lucas GM; Chawarski M; Ruan Y; Richardson P; Shin K; Chen RY; Sugarman J; Dye BJ; Rose SM; Beauchamp G; Burns DN;
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):554-61. PubMed ID: 25564105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
    Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
    Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.
    Lucas GM; Beauchamp G; Aramrattana A; Shao Y; Liu W; Fu L; Jackson JB; Celentano DD; Richardson P; Metzger D;
    Int J Drug Policy; 2012 Mar; 23(2):162-5. PubMed ID: 21852093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
    Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risky Sexual Behavior Among Individuals Receiving Buprenorphine/Naloxone Opiate Dependency Treatment: HIV Prevention Trials Network (HPTN) 058.
    Shava E; Lipira LE; Beauchamp GG; Donnell DJ; Lockman S; Ruan Y; Shao Y
    J Acquir Immune Defic Syndr; 2018 Jul; 78(3):300-307. PubMed ID: 29557855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
    Vergara-Rodriguez P; Tozzi MJ; Botsko M; Nandi V; Altice F; Egan JE; O'Connor PG; Sullivan LE; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S62-7. PubMed ID: 21317596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
    Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
    Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.
    Miller WC; Hoffman IF; Hanscom BS; Ha TV; Dumchev K; Djoerban Z; Rose SM; Latkin CA; Metzger DS; Lancaster KE; Go VF; Dvoriak S; Mollan KR; Reifeis SA; Piwowar-Manning EM; Richardson P; Hudgens MG; Hamilton EL; Sugarman J; Eshleman SH; Susami H; Chu VA; Djauzi S; Kiriazova T; Bui DD; Strathdee SA; Burns DN
    Lancet; 2018 Sep; 392(10149):747-759. PubMed ID: 30191830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
    Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
    Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.
    Ling W; Amass L; Shoptaw S; Annon JJ; Hillhouse M; Babcock D; Brigham G; Harrer J; Reid M; Muir J; Buchan B; Orr D; Woody G; Krejci J; Ziedonis D;
    Addiction; 2005 Aug; 100(8):1090-100. PubMed ID: 16042639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
    Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
    J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
    Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
    J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
    Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
    Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.
    Korthuis PT; Tozzi MJ; Nandi V; Fiellin DA; Weiss L; Egan JE; Botsko M; Acosta A; Gourevitch MN; Hersh D; Hsu J; Boverman J; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S39-45. PubMed ID: 21317593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.